- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01488227
A Prospective Trial on the Effects of Vitamin D Supplementation in Collegiate Swimmers and Divers
A Prospective Trial on the Effects of Vitamin D Supplementation on 25(OH)D, Body Composition and Injury in Collegiate Swimmers and Divers
Objective 1: Determine if Vitamin D supplementation can improve body composition, reduce injuries and illnesses, and improve performance in collegiate swimmers and divers.
Objective 2: Examine how baseline Vitamin D levels predict outcome variables over the course of the intervention period.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The investigators plan to recruit from approximately 45 male and female University of Kentucky Swimmers and Divers, at least 18 years of age in August 2011. Approximately equal numbers of men and women will be recruited. The entire athletic team(s) will be recruited. With a conservative dropout rate of 30%, the investigators final sample size should be approximately 22 participants (per group).Following baseline measures, participants will be randomized to one of two groups (Vitamin D 4000 IU or Placebo control) and monitored over the course of their athletic season. Measurements will be repeated at Midpoint (3 months) and Endpoint (6 months).
Participants will have no recent history of Vitamin D supplementation beyond what is normally found in a multivitamin (400 IUs).
Following the informed consent process a medical history and Vitamin D questionnaire (screenings), and urine pregnancy test (for female athletes) will be administered prior to more invasive baseline testing procedures (blood draw and DXA). A blood draw will then be conducted at baseline, midpoint and endpoint. Collected blood for the purposes of this study will assess Vitamin D status (25(OH)D), parathyroid hormone, ionized calcium, bone turnover markers, and inflammatory cytokines. A Vitamin D lifestyle questionnaire will be administered at all 3 time points and incidence of illness and injury will be documented over 6 months following randomization. DXA measures will only occur at Baseline and Endpoint.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40506
- University of Kentucky
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- University of Kentucky Swimmers and Divers, at least 18 years old.
- No recent history of Vitamin D supplementation beyond 400IU
Exclusion Criteria:
- hormone replacement therapy,
- high dose Vitamin D supplementation,
- history of renal disease or kidney stones,
- organ transplantation,
- sarcoidosis,
- parathyroid disease,
- history of high blood calcium levels.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Vitamin D
|
4000 IU of Vitamin D daily for 6 months
Andre navn:
|
|
Placebo komparator: Oil pill
Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
|
Acts as a control for the Vitamin D intervention
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
25(OH)D)
Tidsramme: 3 measurement periods over 6 months
|
Baseline, Midpoint, and Endpoint measures include a blood draw for 25(OH)D status.
|
3 measurement periods over 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Inflammatory Cytokines
Tidsramme: Baseline and Enpoint
|
Baselineand Endpoint measures include a blood draw inflammatory cytokines (TNF alpha, IL1-B, IL6)
|
Baseline and Enpoint
|
|
Bone Turnover Markers
Tidsramme: Baseline, Midpoint, Endpoint
|
Baseline, Midpoint, and Endpoint measures include a blood draw for bone turnover markers (BSAP, NTx).
|
Baseline, Midpoint, Endpoint
|
|
DXA Body Composition
Tidsramme: Baseline and Endpoint
|
Baseline and Endpoint measures include Body Composition measures (DXA) for fat, muscle and bone composition
|
Baseline and Endpoint
|
|
Vitamin D Lifestyle Survey
Tidsramme: Baseline, Midpoint, Endpoint
|
Baseline, Midpoint, and Endpoint measures include a behavioral survey for estimating 25(OH)D status (solar exposure, food and other supplemental intake)
|
Baseline, Midpoint, Endpoint
|
|
injury and illness incidence
Tidsramme: 6 months
|
We will track injury and illness type and incidence over the course of the 6 month intervention
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Maja Redzic, B.S., University of Kentucky
- Studieleder: Regina M Lewis, B.S., University of Kentucky
- Hovedetterforsker: David T Thomas, PhD, University of Kentucky
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UL1RR033173 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .